Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02657993|
Recruitment Status : Recruiting
First Posted : January 18, 2016
Last Update Posted : August 6, 2019
|Condition or disease||Intervention/treatment||Phase|
|Breast Neoplasms Musculoskeletal Pain||Behavioral: Hypnosis Behavioral: Attention Control||Not Applicable|
The primary purpose of this study is to evaluate the efficacy of hypnosis for reducing musculoskeletal pain (MSP) in women taking aromatase inhibitors (AIs) for breast cancer. Research indicates that AIs are associated with musculoskeletal pain in up to 61% of breast cancer survivors. AI-associated MSP can include joint pain in the wrists, hands, and knees; carpal tunnel syndrome and trigger finger; and decreased grip strength, morning stiffness, and general muscle pain. MSP can lead to difficulty performing daily activities and can reduce quality of life in breast cancer survivors. This pain is not only aversive in and of itself, but also is associated with non-adherence to prescribed, daily AI regimens. In some studies, AI non-adherence estimates were as high as 50%.
At the present time, there is no "gold standard" treatment for AI-associated MSP. What is needed is an intervention that: reduces breast cancer survivors' MSP and helps them be more adherent to their prescribed AI regimen, does not have side-effects of its own, does not place a large time or financial burden on survivors, and which can be taught to survivors to practice on their own.
Hypnosis, a mind-body intervention, has been widely demonstrated to reduce pain. In fact, analgesia is perhaps the best known effect of hypnosis. Meta-analyses have consistently supported the efficacy of hypnosis for pain control, including chronic pain. Hypnosis also has a long tradition in cancer symptom management, especially for pain reduction. Hypnosis has been defined as an agreement between a person designated as the hypnotist (e.g., health care professional) and a person designated as the client or patient to participate in a psychotherapeutic technique based on the hypnotist providing suggestions for changes in sensation, perception, cognition, affect, mood, or behavior.
This study will examine whether or not hypnosis is helpful in reducing breast cancer survivors' AI-related MSP and in improving their adherence to their prescribed AI regimen. This study will also examine whether the hypnosis intervention is cost effective. To answer these questions, this randomized clinical trial will compare hypnosis (three sessions) to a non-hypnosis, attention control, empathic listening condition (three sessions). For each intervention, the first session will be approximately 40 minutes, and sessions 2 and 3 will be approximately 30 minutes each. Both interventions will be delivered face-to-face, by a doctoral-level psychology professional.
All participants will be taking AIs for breast cancer, will be experiencing some musculoskeletal pain since starting AIs (≥3 on a 10 point scale), and will be randomized to one of the two intervention groups. Study participants will be asked to complete measures of pain, AI adherence, and other behavioral and psychosocial measures over the course of 12-month period. The follow-up assessments will evaluate the clinical efficacy and cost-effectiveness of hypnosis versus professional attention.
Overall, this project is a critical step towards reducing the struggles of breast cancer survivors experiencing AI-related MSP, and associated non-adherence. By reducing MSP and improving AI adherence, the hypnosis intervention tested here has the potential to improve quality of life and well-being.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Official Title:||Hypnosis to Reduce Aromatase Inhibitor (AI) Associated Musculoskeletal Pain and to Improve AI Adherence: An RCT to Explore Efficacy and Cost Effects|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||January 2020|
The hypnosis intervention involves three, face-to-face, hypnosis sessions delivered by doctoral-level psychology professionals
The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.
Participants will be asked to complete questionnaires over a period of 12 months.
Active Comparator: Attention Control (Non-Hypnosis)
The attention control intervention is matched to the hypnosis intervention in terms of the amount of professional time received by patients.
Behavioral: Attention Control
The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.
Participants will be asked to complete questionnaires over a period of 12 months.
Other Name: Non-Hypnosis
- Patient-reported musculoskeletal pain (MSP) as measured by the Brief Pain Inventory-Short Form (BPI-SF) [ Time Frame: 12 months ]The Brief Pain Inventory-Short Form (BPI-SF) is a self-report questionnaire assessing pain.
- eCap measure [ Time Frame: 12 months ]Adherence to aromatase inhibitors as measured by the eCap system. The eCap system is a medication event monitoring system that tracks medication usage without active patient input. eCaps record the date and time whenever the cap is opened to remove a pill.
- The Australian/Canadian Osteoarthritis Hand Index (AUSCAN) [ Time Frame: 12 months ]AUSCAN is a self-report measure of musculoskeletal pain.
- The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [ Time Frame: 12 months ]WOMAC is a self-report measure of musculoskeletal pain.
- The Breast Cancer Prevention Trial-Musculoskeletal Symptom (BCPT-MS) [ Time Frame: 12 months ]BCPT-MS is a self-report measure of musculoskeletal pain.
- The Medication Adherence Report Scale (MARS) [ Time Frame: 12 months ]MARS is a self-reported measure of AI adherence.
- The Healthcare Consumption, Illness and Work Questionnaire (Adapted TiC-P) [ Time Frame: 12 months ]Adapted TiC-P is a self-report measure to calculate costs associated with AI-related musculoskeletal pain.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02657993
|Contact: Ashley Berthoumieuxfirstname.lastname@example.org|
|United States, New York|
|Icahn School of Medicine at Mount Sinai||Recruiting|
|New York, New York, United States, 10029|
|Contact: Ashley Berthoumieux 212-659-5521 email@example.com|
|Principal Investigator: Guy H Montgomery, Ph.D.|
|Principal Investigator:||Guy H Montgomery, PhD||Icahn School of Medicine at Mount Sinai|